We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$1.94B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
+47.39%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$441M
(+29%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
50.91%
Holding
78
New
12
Increased
23
Reduced
21
Closed
13
Top Buys
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$49.2M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$40.6M |
| 3 |
United Therapeutics
UTHR
|
+$39.8M |
| 4 |
Cytokinetics
CYTK
|
+$36.5M |
| 5 |
ABVX
Abivax
ABVX
|
+$32.5M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$68.5M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$36.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$34M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$27.8M |
| 5 |
Erasca
ERAS
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arcus Biosciences
RCUS
$3.52B
| $25.9M | 1.33% |
+1,200,000
| New | +$25.9M |
|
27
Dyne Therapeutics
DYN
$3.97B
| $25.4M | 1.31% |
1,400,000
+150,000
| +12% | +$2.59M |
|
28
Structure Therapeutics
GPCR
$3.53B
| $24.1M | 1.24% |
500,000
-100,000
| -17% | -$6.84M |
|
|
LBRX
29
LB Pharmaceuticals
LBRX
$922M
| $22.6M | 1.16% |
915,000
-285,000
| -24% | -$6.57M |
|
30
Enliven Therapeutics
ELVN
$3.8B
| $21.2M | 1.09% |
540,000
+200,000
| +59% | +$5.54M |
|
31
Design Therapeutics
DSGN
$844M
| $20.7M | 1.07% |
1,950,000
-550,000
| -22% | -$5.57M |
|
32
Minerva Neurosciences
NERV
$201M
| $19.4M | 1% |
3,215,000
-96,000
| -3% | -$551K |
|
33
NewAmsterdam Pharma
NAMS
$3.74B
| $19.2M | 0.99% |
600,000
+150,000
| +33% | +$4.89M |
|
34
Mirum Pharmaceuticals
MIRM
$7.38B
| $18.5M | 0.95% |
200,000
-25,000
| -11% | -$2.35M |
|
35
Vaxcyte
PCVX
$8.19B
| $17.4M | 0.9% |
300,000
-350,000
| -54% | -$19M |
|
36
Acadia Pharmaceuticals
ACAD
$4.44B
| $16.7M | 0.86% |
750,000
-100,000
| -12% | -$2.39M |
|
37
Compass Therapeutics
CMPX
$385M
| $16.7M | 0.86% |
3,150,000
+2,000,000
| +174% | +$11.5M |
|
38
Celldex Therapeutics
CLDX
$3.01B
| $14.3M | 0.74% |
450,000
+100,000
| +29% | +$2.73M |
|
39
Janux Therapeutics
JANX
$978M
| $13.9M | 0.72% |
1,000,000
| – | – |
|
40
Vor Biopharma
VOR
$980M
| $13.4M | 0.69% |
750,000
+650,000
| +650% | +$9.17M |
|
41
Alkermes
ALKS
$8.66B
| $12.4M | 0.64% |
+350,000
| New | +$10.9M |
|
42
Oric Pharmaceuticals
ORIC
$1.15B
| $12M | 0.62% |
950,000
+500,000
| +111% | +$5.68M |
|
43
Immix Biopharma
IMMX
$750M
| $11.2M | 0.57% |
1,225,000
+225,000
| +23% | +$1.65M |
|
44
Tenax Therapeutics
TENX
$407M
| $9.99M | 0.51% |
+625,000
| New | +$8.46M |
|
45
Amylyx Pharmaceuticals
AMLX
$1.98B
| $9.73M | 0.5% |
700,000
-250,000
| -26% | -$3.52M |
|
|
CBIO
46
Crescent Biopharma
CBIO
$432M
| $8.86M | 0.46% |
482,500
-117,500
| -20% | -$1.35M |
|
|
SLNO
47
DELISTED
Soleno Therapeutics
SLNO
| $8.37M | 0.43% |
250,000
-50,000
| -17% | -$1.96M |
|
48
ArriVent BioPharma
AVBP
$1.53B
| $8.07M | 0.42% |
+350,000
| New | +$7.9M |
|
49
Relay Therapeutics
RLAY
$4.25B
| $7.46M | 0.38% |
+750,000
| New | +$6.71M |
|
50
Corvus Pharmaceuticals
CRVS
$1.25B
| $6.58M | 0.34% |
450,000
-50,000
| -10% | -$798K |
|
Similar funds
NFG
FFH
BC
MWA
WPC
OCM
1SB
FM